Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.48 NOK | +0.37% | -6.48% | +12.76% |
Business Summary
Number of employees: 8
Sales per Business
NOK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Oncolytic Peptides
100.0
%
| 17 | 100.0 % | 4 | 100.0 % | -76.89% |
Sales per region
NOK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 11 | 63.9 % | 4 | 100.0 % | -63.82% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Øystein Rekdal
CEO | Chief Executive Officer | - | 31/12/02 |
Gjest Breistein
DFI | Director of Finance/CFO | - | - |
Chief Tech/Sci/R&D Officer | - | 31/12/07 | |
Gry Stensrud
CTO | Chief Tech/Sci/R&D Officer | 54 | - |
Ole Peter Nordby
IRC | Investor Relations Contact | - | - |
- | - | ||
Stephen Worsley
PRN | Corporate Officer/Principal | 60 | 05/09/22 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Kjetil Hestdal
BRD | Director/Board Member | 64 | 06/06/21 |
Director/Board Member | 66 | 06/06/21 | |
Jayson M. Rieger
BRD | Director/Board Member | 48 | 06/06/21 |
Øystein Rekdal
CEO | Chief Executive Officer | - | 31/12/02 |
Marie Roskrow
CHM | Chairman | - | 17/04/23 |
Evelina Vågesjö
BRD | Director/Board Member | 38 | 06/06/21 |
Director/Board Member | 59 | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 50,578,121 | 29,872,541 ( 59.06 %) | 0 | 59.06 % |
Company contact information
Sector
Sales per region
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+12.76% | 20.24M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- LYTIX Stock
- Company Lytix Biopharma